Search results
Results From The WOW.Com Content Network
Apixaban. Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [ 6][ 7][ 8] Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a ...
Diazepam. Diazepam, sold under the brand name Valium among others, is a medicine of the benzodiazepine family that acts as an anxiolytic. [ 14] It is used to treat a range of conditions, including anxiety, seizures, alcohol withdrawal syndrome, muscle spasms, insomnia, and restless legs syndrome. [ 14]
Buspirone, sold under the brand name Buspar, among others, is an anxiolytic, a medication primarily used to treat anxiety disorders, particularly generalized anxiety disorder. [ 10][ 11] It is a serotonin 5-HT 1A receptor agonist, increasing action at serotonin receptors in the brain. [ 3]
Leqembi’s side effects and other potential issues. Leqembi offers doctors the first new Alzheimer’s treatment option in years. But it also has some possibly dangerous side effects. Those ...
Sedation is the side effect people taking lorazepam most frequently report. In a group of around 3,500 people treated for anxiety, the most common side effects complained of from lorazepam were sedation (15.9%), dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Side effects such as sedation and unsteadiness increased with age. [52]
The CDC lists the following as possible side effects of the RSV vaccine: Pain, redness, and swelling where the shot is given. Fatigue. Fever. Headache. Nausea. Diarrhea. Muscle or joint pain ...
By Manas Mishra and Puyaan Singh. (Reuters) -The European Union's drugs regulator has rejected Eisai and Biogen's Leqembi treatment for early Alzheimer's disease, saying the risk of serious brain ...
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...